Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production

Nir Barzilai, Meredith A. Hawkins, Ivo Angelov, Meizhu Hu, Luciano Rossetti

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Although the kinetic characteristics of hepatic glucokinase (GK) suggest its potential role as the hepatic 'glucose sensor,' its impact on the regulation of in vivo hepatic glucose production (HGP) is still controversial. Since decreased GK activity has been linked to experimental and human diabetes, we examined whether a moderate and transient inhibition of GK activity diminishes the ability of hyperglycemia to suppress HGP. We first determined the concentration of the competitive inhibitor, glucosamine (GlcN), which decreases hepatic GK activity by ~60% in vitro. GlcN was then infused into conscious rats to achieve a similar inhibition of the in vivo GK activity (plasma GlcN levels = ~2 mmol/l; rats infused with saline served as control, n = 20). To maintain equal plasma insulin and glucagon concentrations throughout the studies, somatostatin and insulin (basal replacement) were infused for 4 h. [3-3H]-glucose and [U-14C]-lactate were infused to measure HGP, gluconeogenesis, and glucose cycling (GC) during 2 h of euglycemia (glucose ~8 mmol/l) followed by 2 h of hyperglycemia (glucose ~18 mmol/l). Our results support the notion that hepatic GK activity is indeed decreased by GIcN in vivo. In fact, in response to hyperglycemia the 'direct' pathway of hepatic glucose-6-phosphate (G-6-P) formation was ~40% lower with GlcN compared with saline infusion (37 ± 3 vs. 63 ± 3%; P < 0.001). Furthermore, while hyperglycemia stimulated GC by ~2.5-fold during saline infusion (from 3.0 ± 0.6 to 7.7 ± 1.4 mg · kg · min-1, p < 0.001, euglycemia vs. hyperglycemia), this increase was blunted in the presence of GlcN (4.6 ± 0.6 mg · kg-1 · min-1, P = NS). Finally, in the presence of GlcN, the hepatic concentration of G-6-P was decreased by ~40% compared with saline (234 ± 38 and 390 ± 24 nmol/g, P < 0.01). During the euglycemic studies, HGP was similar (12.6 ± 0.6 and 11.3 ± 0.2 mg · kg-1 · min-1 with GlcN or saline infusion, respectively). However, while hyperglycemia per se suppressed HGP by ~65%, HGP was inhibited by ~38% and it was approximately twofold higher than in the saline-infused rats (7.8 ± 0.8 and 4.0 ± 0.3 mg · kg-1 · min-1, P < 0.01) in the presence of GlcN-induced inhibition of hepatic GK. This increase in HGP was largely accounted for by the decreased inhibition of hepatic net glycogenolysis by hyperglycemia (3.3 ± 0.8 and 1.1 ± 0.3 mg · kg-1 · min-1 with GlcN or saline infusion, respectively, P < 0.01). We conclude that intact GK activity is required for the normal suppression of HGP by hyperglycemia and its impairment may contribute to increased HGP in experimental and human diabetes.

Original languageEnglish (US)
Pages (from-to)1329-1335
Number of pages7
JournalDiabetes
Volume45
Issue number10
StatePublished - 1996

Fingerprint

Glucokinase
Glucosamine
Hyperglycemia
Glucose
Liver
Glucose-6-Phosphate
Insulin
Glycogenolysis
Gluconeogenesis

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production. / Barzilai, Nir; Hawkins, Meredith A.; Angelov, Ivo; Hu, Meizhu; Rossetti, Luciano.

In: Diabetes, Vol. 45, No. 10, 1996, p. 1329-1335.

Research output: Contribution to journalArticle

@article{6e6ff16ebcc944afab8b7bc798f15a89,
title = "Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production",
abstract = "Although the kinetic characteristics of hepatic glucokinase (GK) suggest its potential role as the hepatic 'glucose sensor,' its impact on the regulation of in vivo hepatic glucose production (HGP) is still controversial. Since decreased GK activity has been linked to experimental and human diabetes, we examined whether a moderate and transient inhibition of GK activity diminishes the ability of hyperglycemia to suppress HGP. We first determined the concentration of the competitive inhibitor, glucosamine (GlcN), which decreases hepatic GK activity by ~60{\%} in vitro. GlcN was then infused into conscious rats to achieve a similar inhibition of the in vivo GK activity (plasma GlcN levels = ~2 mmol/l; rats infused with saline served as control, n = 20). To maintain equal plasma insulin and glucagon concentrations throughout the studies, somatostatin and insulin (basal replacement) were infused for 4 h. [3-3H]-glucose and [U-14C]-lactate were infused to measure HGP, gluconeogenesis, and glucose cycling (GC) during 2 h of euglycemia (glucose ~8 mmol/l) followed by 2 h of hyperglycemia (glucose ~18 mmol/l). Our results support the notion that hepatic GK activity is indeed decreased by GIcN in vivo. In fact, in response to hyperglycemia the 'direct' pathway of hepatic glucose-6-phosphate (G-6-P) formation was ~40{\%} lower with GlcN compared with saline infusion (37 ± 3 vs. 63 ± 3{\%}; P < 0.001). Furthermore, while hyperglycemia stimulated GC by ~2.5-fold during saline infusion (from 3.0 ± 0.6 to 7.7 ± 1.4 mg · kg · min-1, p < 0.001, euglycemia vs. hyperglycemia), this increase was blunted in the presence of GlcN (4.6 ± 0.6 mg · kg-1 · min-1, P = NS). Finally, in the presence of GlcN, the hepatic concentration of G-6-P was decreased by ~40{\%} compared with saline (234 ± 38 and 390 ± 24 nmol/g, P < 0.01). During the euglycemic studies, HGP was similar (12.6 ± 0.6 and 11.3 ± 0.2 mg · kg-1 · min-1 with GlcN or saline infusion, respectively). However, while hyperglycemia per se suppressed HGP by ~65{\%}, HGP was inhibited by ~38{\%} and it was approximately twofold higher than in the saline-infused rats (7.8 ± 0.8 and 4.0 ± 0.3 mg · kg-1 · min-1, P < 0.01) in the presence of GlcN-induced inhibition of hepatic GK. This increase in HGP was largely accounted for by the decreased inhibition of hepatic net glycogenolysis by hyperglycemia (3.3 ± 0.8 and 1.1 ± 0.3 mg · kg-1 · min-1 with GlcN or saline infusion, respectively, P < 0.01). We conclude that intact GK activity is required for the normal suppression of HGP by hyperglycemia and its impairment may contribute to increased HGP in experimental and human diabetes.",
author = "Nir Barzilai and Hawkins, {Meredith A.} and Ivo Angelov and Meizhu Hu and Luciano Rossetti",
year = "1996",
language = "English (US)",
volume = "45",
pages = "1329--1335",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production

AU - Barzilai, Nir

AU - Hawkins, Meredith A.

AU - Angelov, Ivo

AU - Hu, Meizhu

AU - Rossetti, Luciano

PY - 1996

Y1 - 1996

N2 - Although the kinetic characteristics of hepatic glucokinase (GK) suggest its potential role as the hepatic 'glucose sensor,' its impact on the regulation of in vivo hepatic glucose production (HGP) is still controversial. Since decreased GK activity has been linked to experimental and human diabetes, we examined whether a moderate and transient inhibition of GK activity diminishes the ability of hyperglycemia to suppress HGP. We first determined the concentration of the competitive inhibitor, glucosamine (GlcN), which decreases hepatic GK activity by ~60% in vitro. GlcN was then infused into conscious rats to achieve a similar inhibition of the in vivo GK activity (plasma GlcN levels = ~2 mmol/l; rats infused with saline served as control, n = 20). To maintain equal plasma insulin and glucagon concentrations throughout the studies, somatostatin and insulin (basal replacement) were infused for 4 h. [3-3H]-glucose and [U-14C]-lactate were infused to measure HGP, gluconeogenesis, and glucose cycling (GC) during 2 h of euglycemia (glucose ~8 mmol/l) followed by 2 h of hyperglycemia (glucose ~18 mmol/l). Our results support the notion that hepatic GK activity is indeed decreased by GIcN in vivo. In fact, in response to hyperglycemia the 'direct' pathway of hepatic glucose-6-phosphate (G-6-P) formation was ~40% lower with GlcN compared with saline infusion (37 ± 3 vs. 63 ± 3%; P < 0.001). Furthermore, while hyperglycemia stimulated GC by ~2.5-fold during saline infusion (from 3.0 ± 0.6 to 7.7 ± 1.4 mg · kg · min-1, p < 0.001, euglycemia vs. hyperglycemia), this increase was blunted in the presence of GlcN (4.6 ± 0.6 mg · kg-1 · min-1, P = NS). Finally, in the presence of GlcN, the hepatic concentration of G-6-P was decreased by ~40% compared with saline (234 ± 38 and 390 ± 24 nmol/g, P < 0.01). During the euglycemic studies, HGP was similar (12.6 ± 0.6 and 11.3 ± 0.2 mg · kg-1 · min-1 with GlcN or saline infusion, respectively). However, while hyperglycemia per se suppressed HGP by ~65%, HGP was inhibited by ~38% and it was approximately twofold higher than in the saline-infused rats (7.8 ± 0.8 and 4.0 ± 0.3 mg · kg-1 · min-1, P < 0.01) in the presence of GlcN-induced inhibition of hepatic GK. This increase in HGP was largely accounted for by the decreased inhibition of hepatic net glycogenolysis by hyperglycemia (3.3 ± 0.8 and 1.1 ± 0.3 mg · kg-1 · min-1 with GlcN or saline infusion, respectively, P < 0.01). We conclude that intact GK activity is required for the normal suppression of HGP by hyperglycemia and its impairment may contribute to increased HGP in experimental and human diabetes.

AB - Although the kinetic characteristics of hepatic glucokinase (GK) suggest its potential role as the hepatic 'glucose sensor,' its impact on the regulation of in vivo hepatic glucose production (HGP) is still controversial. Since decreased GK activity has been linked to experimental and human diabetes, we examined whether a moderate and transient inhibition of GK activity diminishes the ability of hyperglycemia to suppress HGP. We first determined the concentration of the competitive inhibitor, glucosamine (GlcN), which decreases hepatic GK activity by ~60% in vitro. GlcN was then infused into conscious rats to achieve a similar inhibition of the in vivo GK activity (plasma GlcN levels = ~2 mmol/l; rats infused with saline served as control, n = 20). To maintain equal plasma insulin and glucagon concentrations throughout the studies, somatostatin and insulin (basal replacement) were infused for 4 h. [3-3H]-glucose and [U-14C]-lactate were infused to measure HGP, gluconeogenesis, and glucose cycling (GC) during 2 h of euglycemia (glucose ~8 mmol/l) followed by 2 h of hyperglycemia (glucose ~18 mmol/l). Our results support the notion that hepatic GK activity is indeed decreased by GIcN in vivo. In fact, in response to hyperglycemia the 'direct' pathway of hepatic glucose-6-phosphate (G-6-P) formation was ~40% lower with GlcN compared with saline infusion (37 ± 3 vs. 63 ± 3%; P < 0.001). Furthermore, while hyperglycemia stimulated GC by ~2.5-fold during saline infusion (from 3.0 ± 0.6 to 7.7 ± 1.4 mg · kg · min-1, p < 0.001, euglycemia vs. hyperglycemia), this increase was blunted in the presence of GlcN (4.6 ± 0.6 mg · kg-1 · min-1, P = NS). Finally, in the presence of GlcN, the hepatic concentration of G-6-P was decreased by ~40% compared with saline (234 ± 38 and 390 ± 24 nmol/g, P < 0.01). During the euglycemic studies, HGP was similar (12.6 ± 0.6 and 11.3 ± 0.2 mg · kg-1 · min-1 with GlcN or saline infusion, respectively). However, while hyperglycemia per se suppressed HGP by ~65%, HGP was inhibited by ~38% and it was approximately twofold higher than in the saline-infused rats (7.8 ± 0.8 and 4.0 ± 0.3 mg · kg-1 · min-1, P < 0.01) in the presence of GlcN-induced inhibition of hepatic GK. This increase in HGP was largely accounted for by the decreased inhibition of hepatic net glycogenolysis by hyperglycemia (3.3 ± 0.8 and 1.1 ± 0.3 mg · kg-1 · min-1 with GlcN or saline infusion, respectively, P < 0.01). We conclude that intact GK activity is required for the normal suppression of HGP by hyperglycemia and its impairment may contribute to increased HGP in experimental and human diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0029785315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029785315&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 1329

EP - 1335

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -